BIO-TECHNE TO PRESENT AT THE COWEN 43rd ANNUAL HEALTH CARE CONFERENCE

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 2:10 p.m. EST.

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 2:10 p.m. EST. Investors can access a live webcast of the presentation through the company's Investor Relations website.

Bio-Techne is a prominent developer of purified proteins and reagent solutions, including cytokines, antibodies, and diagnostic products. The company generated approximately $1.1 billion in net sales for fiscal 2022 and employs around 3,000 people globally.

Argus Session date unavailable

-0.06% session move Open Argus

Details

News Market Reaction – TECH

The recorded move for TECH in the trading session of this news was -0.06%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Feb. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Cowen 43^rd Annual Health Care Conference on Monday, March 6, 2023, at 2:10 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.

Contact:	David Clair, Vice President, Investor Relations & Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-cowen-43rd-annual-health-care-conference-301758104.html

SOURCE Bio-Techne Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Bio-Techne present at the Cowen 43rd Annual Health Care Conference?

Bio-Techne will present on March 6, 2023, at 2:10 p.m. EST.

Who is presenting for Bio-Techne at the conference?

CEO Chuck Kummeth will present at the conference.

How can I watch the Bio-Techne conference presentation?

A live webcast can be accessed via Bio-Techne's Investor Relations website.

What are Bio-Techne's main products?

Bio-Techne develops purified proteins, reagents, diagnostic products, and genomic tools.

What was Bio-Techne's revenue for fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.